---
aliases: [ABBV]
---
#actor #pharma #immunology #usa #public

**AbbVie** — Immunology leader. Skyrizi/Rinvoq replacing Humira. $61B revenue guidance. Post-patent pivot success.

---

## Why AbbVie matters

| Metric | Value |
|--------|-------|
| Ticker | ABBV (NYSE) |
| 2025 revenue guidance | **$60.9B** (raised 3x) |
| Skyrizi + Rinvoq | **$25B+** combined (2025) |
| Humira | <$1B/quarter (down 55%) |

---

## Key products

| Product | Q3 2025 Revenue | Growth |
|---------|-----------------|--------|
| **Skyrizi** | $4.7B | +47% YoY |
| **Rinvoq** | $2.2B | +35% YoY |
| Humira | $993M | -55% YoY |

**Milestone:** Q3 2025 first time Humira <$1B since 2007.

---

## Post-Humira pivot

| Year | Humira Status | Skyrizi/Rinvoq |
|------|---------------|----------------|
| 2022 | $21B peak | Growing |
| 2023 | Biosimilar entry | $14B combined |
| 2025 | <$4B run-rate | **$25B+** combined |

**Success story:** Only 20% of Humira patients moved to biosimilars — many converted to Skyrizi/Rinvoq.

---

## Franchise breakdown

### Immunology
- Skyrizi: Psoriasis, IBD (50% market share in Crohn's/UC)
- Rinvoq: Rheumatoid arthritis, atopic dermatitis

### Oncology
- Imbruvica, Venclexta

### Aesthetics
- Botox (Allergan acquisition)

### Neuroscience
- Vraylar, migraine portfolio

---

## Financial performance

| Metric | 2025E |
|--------|-------|
| Revenue | $60.9B |
| Growth driver | Skyrizi/Rinvoq +22% |
| Guidance raises | 3x in 2025 |

---

## Investment case

**Bull:**
- Successful Humira transition
- Skyrizi/Rinvoq growth runway
- Diversified portfolio (Botox, oncology)
- Strong dividend

**Bear:**
- Rinvoq safety label concerns
- Biosimilar pressure continues
- High debt from Allergan deal
- Competition in immunology

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | ABBV |
| Exchange | NYSE |
| Revenue | ~$61B |
| Focus | Immunology, oncology |

---

## Related

- [[Biopharma]] — sector
- [[Amgen]] — biosimilar competitor

---

## Sources

- [AbbVie Q3 2025 results](https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2025-financial-results)
- [Fierce Pharma](https://www.fiercepharma.com/pharma/abbvie-boosts-revenue-forecast-again-thanks-booming-sales-skyrizi-rinvoq)

*Created 2026-01-09*
